369 related articles for article (PubMed ID: 17363502)
1. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
Chekhun VF; Lukyanova NY; Kovalchuk O; Tryndyak VP; Pogribny IP
Mol Cancer Ther; 2007 Mar; 6(3):1089-98. PubMed ID: 17363502
[TBL] [Abstract][Full Text] [Related]
2. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins.
Tryndyak VP; Kovalchuk O; Pogribny IP
Cancer Biol Ther; 2006 Jan; 5(1):65-70. PubMed ID: 16322686
[TBL] [Abstract][Full Text] [Related]
3. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Pogribny IP; Ross SA; Tryndyak VP; Pogribna M; Poirier LA; Karpinets TV
Carcinogenesis; 2006 Jun; 27(6):1180-6. PubMed ID: 16497704
[TBL] [Abstract][Full Text] [Related]
4. Modulation of intracellular iron metabolism by iron chelation affects chromatin remodeling proteins and corresponding epigenetic modifications in breast cancer cells and increases their sensitivity to chemotherapeutic agents.
Pogribny IP; Tryndyak VP; Pogribna M; Shpyleva S; Surratt G; Gamboa da Costa G; Beland FA
Int J Oncol; 2013 May; 42(5):1822-32. PubMed ID: 23483119
[TBL] [Abstract][Full Text] [Related]
5. Modulation of DNA methylation levels sensitizes doxorubicin-resistant breast adenocarcinoma cells to radiation-induced apoptosis.
Luzhna L; Kovalchuk O
Biochem Biophys Res Commun; 2010 Feb; 392(2):113-7. PubMed ID: 20034463
[TBL] [Abstract][Full Text] [Related]
6. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
7. Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells.
Chang YW; Singh KP
PLoS One; 2017; 12(3):e0174227. PubMed ID: 28323900
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
9. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
10. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
11. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
Chekhun VF; Kulik GI; Yurchenko OV; Tryndyak VP; Todor IN; Luniv LS; Tregubova NA; Pryzimirska TV; Montgomery B; Rusetskaya NV; Pogribny IP
Cancer Lett; 2006 Jan; 231(1):87-93. PubMed ID: 16356834
[TBL] [Abstract][Full Text] [Related]
12. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
13. Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.
Ponnusamy L; Mahalingaiah PKS; Chang YW; Singh KP
Eur J Pharm Sci; 2018 Oct; 123():56-69. PubMed ID: 30016648
[TBL] [Abstract][Full Text] [Related]
14. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
Ogretmen B; McCauley MD; Safa AR
Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic immunomodulatory effect of eugenol and astaxanthin on doxorubicin cytotoxicity in hormonal positive breast Cancer cells.
Fouad MA; Sayed-Ahmed MM; Huwait EA; Hafez HF; Osman AM
BMC Pharmacol Toxicol; 2021 Jan; 22(1):8. PubMed ID: 33509300
[TBL] [Abstract][Full Text] [Related]
18. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer.
Dong C; Wu Y; Yao J; Wang Y; Yu Y; Rychahou PG; Evers BM; Zhou BP
J Clin Invest; 2012 Apr; 122(4):1469-86. PubMed ID: 22406531
[TBL] [Abstract][Full Text] [Related]
19. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
20. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression.
Simpson NE; Tryndyak VP; Beland FA; Pogribny IP
Breast Cancer Res Treat; 2012 Jun; 133(3):959-68. PubMed ID: 22101407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
